相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
John J. Park et al.
CANCER GENE THERAPY (2022)
HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
Sathya Neelature Sriramareddy et al.
CANCER GENE THERAPY (2022)
KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma
Jia Liu et al.
ANTI-CANCER DRUGS (2022)
CUX2/KDM5B/SOX17 Axis Affects the Occurrence and Development of Breast Cancer
Lili Li et al.
ENDOCRINOLOGY (2022)
MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma
Sathya Neelature Sriramareddy et al.
CLINICAL CANCER RESEARCH (2021)
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
Shang-Min Zhang et al.
NATURE (2021)
Treatment of Metastatic Uveal Melanoma: Systematic Review
Cristina Rodriguez-Vidal et al.
CANCERS (2020)
Clinical Trials in Metastatic Uveal Melanoma: Current Status
Tamara A. Sussman et al.
OCULAR ONCOLOGY AND PATHOLOGY (2020)
Clinical Development of BRAF plus MEK Inhibitor Combinations
Vivek Subbiah et al.
TRENDS IN CANCER (2020)
Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target
Yi-Chao Zheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2 '-Deoxycytidine
Benjamin R. Leadem et al.
CANCER RESEARCH (2018)
Role of Epigenetics in Uveal Melanoma
Yongyun Li et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells
Anthony Tumber et al.
CELL CHEMICAL BIOLOGY (2017)
A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth
Lei Wang et al.
NATURE COMMUNICATIONS (2013)
The Epigenotype
C. H. Waddington
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2012)
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
Marie Cargnello et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Uveal Melanoma: Trends in Incidence, Treatment, and Survival
Arun D. Singh et al.
OPHTHALMOLOGY (2011)
Reversal of Histone Methylation: Biochemical and Molecular Mechanisms of Histone Demethylases
Nima Mosammaparast et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 79 (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Catherine D. Van Raamsdonk et al.
NATURE (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
High-resolution profiling of histone methylations in the human genome
Artern Barski et al.
CELL (2007)
The diverse functions of histone lysine methylation
C Martin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
分享论文
